A word cloud showing the cancer areas we run trials in


Our overarching strategic aims (2017–22) within the Cancer Division of Leeds CTRU are:

  1. To be the Northern Centre of Excellence for the Conduct of Cancer Clinical Trials
  2. To secure additional cancer-specific core funding, to allow us to expand our cutting edge portfolio of early and late phase clinical trials
  3. To build on, strengthen and expand our current strategic relationships within Leeds, and more widely, to ensure access to expertise and infrastructure to deliver the most appropriate, and timely, correlative analyses (e.g. laboratory, imaging)
  4. To deliver a successful innovative and efficient trial portfolio and to be at the forefront of development and implementation of novel and efficient trial design and conduct
  5. To maximise our links to the Leeds MRC Bioinformatics Centre to exploit the opportunities for efficient trial conduct through linkage to routine data sources or large datasets.
  6. To increase our education, training and mentorship opportunities for both CTU staff and clinical researchers (local and national)
  7. To ensure appropriate public and patient engagement throughout the development and delivery of our cancer research portfolio 

Trials and Associated Research

Work with us

We work closely with Senior Management and Clinical Advisors to prioritise the projects we take forward. Collaborative clinical trials are considered according to the following criteria:

  • Fits with the Cancer Divisional Research Strategy
  • Scientific innovation potential
  • Clinical relevance
  • Research experience of the partners
  • Realistic recruitment strategy
  • Available expertise
  • Available and obtainable resources/capacity
  • Potential for development of an ongoing pipeline of research

We are particularly interested in clinical trials which:

  • Address research questions which are important to the NHS
  • Address important clinical problems or scientific questions
  • Contribute to building capacity in the next generation of clinical academic researchers

If you have a clinical trial question which fits with our research strategy please contact us by completing and returning an Expression of interest form.

Local Clinical Advisors

Radiotherapy: Professor David Sebag-Montefiore, Audrey and Stanley Burton Professor of Clinical Oncology and Health Research.

Gastro-Intestinal Cancer: Professor Matt Seymour, Chair of Gastrointestinal Cancer Medicine & Hon. Consultant Medical Oncologist; Director of NCRN (NIHR Cancer Research Network); Clinical Research Director of NCRI (the National Cancer Research Institute)

Haematological Malignancies (Multiple Myeloma): Professor Gordon Cook, Professor of Haematology and Myeloma Studies

Haematological Malignancies (CLL): Professor Peter Hillmen, Professor of Experimental Haematology

Early Phase: Professor Chris Twelves, Professor of Clinical Cancer Pharmacology and Oncology, Clinical Director Leeds CRF